CAS NO: | 141702-36-5 |
生物活性 | Faropenem daloxate is the first oral penem in a new class ofbeta-lactam antibiotics. IC50 Value: Target: Antibacterial Faropenem daloxate is useful for penem andantibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influenzae and other key pathogens implicated in acutebacterialrhinosinusitis. Clinical studies have demonstrated that, in the treatment of acutebacterialrhinosinusitis in adults, 7 days of treatment with faropenem medoxomil is as clinically and bacteriologically effective as 10 days of treatment with cefuroxime axetil. One study showed faropenem medoxomil to be superior to cefuroxime axetil. Overall, the safety profile of faropenem medoxomil is similar to that of most comparators. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
分子量 | 397.40 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C17H19NO8S | ||||||||||||||||
CAS 号 | 141702-36-5 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(251.64 mM) H2O :< 0.1 mg/mL (ultrasonic)(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |